LLY

735.37

+2.56%↑

JNJ

149.01

+1.88%↑

UNH

267.41

-14.14%↓

ABBV

179.84

+0.54%↑

NVO

66.03

+2.79%↑

LLY

735.37

+2.56%↑

JNJ

149.01

+1.88%↑

UNH

267.41

-14.14%↓

ABBV

179.84

+0.54%↑

NVO

66.03

+2.79%↑

LLY

735.37

+2.56%↑

JNJ

149.01

+1.88%↑

UNH

267.41

-14.14%↓

ABBV

179.84

+0.54%↑

NVO

66.03

+2.79%↑

LLY

735.37

+2.56%↑

JNJ

149.01

+1.88%↑

UNH

267.41

-14.14%↓

ABBV

179.84

+0.54%↑

NVO

66.03

+2.79%↑

LLY

735.37

+2.56%↑

JNJ

149.01

+1.88%↑

UNH

267.41

-14.14%↓

ABBV

179.84

+0.54%↑

NVO

66.03

+2.79%↑

Search

Pfizer

Open

SectorGezondheidszorg

22.39 0.86

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

21.97

Max

22.52

Belangrijke statistieken

By Trading Economics

Inkomsten

2.6B

3B

Verkoop

-4B

14B

K/W

Sectorgemiddelde

16.732

56.602

EPS

0.92

Dividendrendement

7.72

Winstmarge

21.633

Werknemers

81,000

EBITDA

2B

4.5B

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+22.17% upside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

7.72%

2.45%

Volgende Winsten

29 jul 2025

Volgende dividenddatum

13 jun 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-14B

131B

Vorige openingsprijs

21.53

Vorige sluitingsprijs

22.39

Nieuwssentiment

By Acuity

38%

62%

128 / 382 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Bullish Evidence

Pfizer Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

1 mei 2025, 18:41 UTC

Belangrijke Marktbewegers

Arvinas Shares Drop; Cancels Two Drug Trials With Pfizer Amid Capital Markets Challenges

29 apr 2025, 11:24 UTC

Winsten

Pfizer 1Q Revenue Slides as Paxlovid Sales Fade

12 mei 2025, 22:14 UTC

Top Nieuws

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- 2nd Update

12 mei 2025, 18:45 UTC

Top Nieuws

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- Update

12 mei 2025, 17:14 UTC

Top Nieuws

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- WSJ

12 mei 2025, 09:02 UTC

Populaire aandelen

Stocks to Watch: Amazon, Tesla, Apple, Maersk -- WSJ

7 mei 2025, 17:01 UTC

Top Nieuws

Teva Will Hike Generic Drug Prices If Trump Imposes Tariffs, CEO Says -- Barrons.com

7 mei 2025, 09:30 UTC

Top Nieuws

Trump Is Threatening Big Pharma With Tariffs. Tax Changes Might Work Better. -- Heard on the Street -- WSJ

5 mei 2025, 15:13 UTC

Marktinformatie
Winsten

Narrower Guidelines for Covid-19 Booster Wouldn't Limit BioNTech's Customer Base Much -- Market Talk

1 mei 2025, 14:07 UTC

Winsten

Eli Lilly Earnings Beat Expectations. Why the Stock Is Falling. -- Barrons.com

1 mei 2025, 11:58 UTC

Winsten

Eli Lilly Earnings Beat Expectations. Why the Stock Is Falling. -- Barrons.com

1 mei 2025, 11:06 UTC

Winsten

Eli Lilly Earnings Beat Expectations. Why the Stock Is Falling. -- Barrons.com

1 mei 2025, 10:48 UTC

Winsten

Eli Lilly Earnings Beat Expectations. The Stock Is Falling. -- Barrons.com

29 apr 2025, 19:47 UTC

Winsten

Pfizer Shares Rise on CEO's Optimism on Threatened Drug Tariffs -- Barrons.com

29 apr 2025, 18:11 UTC

Winsten

Pfizer Stock's 7% Yield Makes It Look Like a Junk Bond -- But Better -- Barrons.com

29 apr 2025, 15:22 UTC

Winsten

Pfizer Earnings Beat Isn't Enough to Ease Stock Worries -- Barrons.com

29 apr 2025, 12:03 UTC

Acquisities, Fusies, Overnames

Pfizer Files 8K - Costs of Exits Or Disposals >PFE

29 apr 2025, 11:46 UTC

Winsten

Pfizer Stock Gains After Earnings Beat. Tariffs Aren't the Only Worry for Wall Street. -- Barrons.com

29 apr 2025, 11:42 UTC

Winsten

Pfizer Stock Falls After Earnings Beat. Tariffs Aren't the Only Worry. -- Barrons.com

29 apr 2025, 11:12 UTC

Winsten

Pfizer Earnings Beat. Tariffs Uncertainty Hinders Guidance. -- Barrons.com

29 apr 2025, 10:52 UTC

Winsten

Pfizer: Currently Trending Towards Upper End of 2025 Adj EPS Guidance Range

29 apr 2025, 10:51 UTC

Winsten

Pfizer: Believe We Can Be Agile in Navigating Uncertain and Volatile External Environment

29 apr 2025, 10:50 UTC

Winsten

Pfizer: On Track For Total Net Cost Savings $5.7B Through 2027

29 apr 2025, 10:47 UTC

Winsten

Pfizer: Expects to Continue to De-Lever in Prudent Manner

29 apr 2025, 10:47 UTC

Winsten

Pfizer: Current Fincl Guidance Does Not Anticipate Any Share Repurchases in 2025

29 apr 2025, 10:46 UTC

Winsten

Pfizer: "Unable to Predict" Tariff Impact "At This Time"

29 apr 2025, 10:45 UTC

Winsten

Pfizer: Reaffirmed Views Don't Currently Include Impact From Tariffs

29 apr 2025, 10:45 UTC

Winsten

Pfizer 1Q EPS 52c >PFE

29 apr 2025, 10:45 UTC

Winsten

Pfizer 1Q Adj EPS 92c >PFE

29 apr 2025, 10:45 UTC

Winsten

Pfizer 1Q Net $2.97B >PFE

Peer Vergelijking

Prijswijziging

Pfizer Prognose

Koersdoel

By TipRanks

22.17% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 27.94 USD  22.17%

Hoogste 32 USD

Laagste 24 USD

Gebaseerd op 18 Wall Street-analisten die 12-maands prijsdoelen bieden voor Pfizer - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

18 ratings

5

Buy

13

Hold

0

Sell

Technische score

By Trading Central

22.855 / 23.85Steun & Weerstand

Korte Termijn

Bullish Evidence

Gemiddeld Termijn

Bearish Evidence

Lange Termijn

Bearish Evidence

Sentiment

By Acuity

128 / 382 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Pfizer

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as has strategic clinical collaboration with Acepodia Inc. for the development of antibody-cell conjugation-based cell therapies in autoimmune diseases. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.